Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily, Mid-Day, 10/5/11, universe is fading, pausing on the way down

The 6 W’s: Who, what, where, when, why and what of it …

The pace of growth in the services sector decelerated slightly in September, according to data Wednesday; 10/5/11 that reinforces a picture of a … slow-moving economy.

Mid-Day: The NASDAQ is UP + 27.59 (+1.15%) to 2,406.48. The Dow is UP +28.76 (+0.27%) to 10,837.47.

Mid-Day Movers: Advanced Cell Technology (OTCF BB: ACTC), Athersys (NASDAQ:ATHX), Brainstorm (OTC BB: BCLI), Cytori (NASDAQ:CYTX), ImmunoCellular (OTC BB: IMUC), NeoStem (AMEX: NBS), Neuralstem (AMEX: CUR), Opexa (OPXA), Osiris (NASDAQ:OSIR), Pluristem (NASDAQ:PSTI), StemCells (STEM), ThermoGenesis (NASDAQ:KOOL) and Tengion (TNGN)

What’s new in the regenerative medicine/stem cell market … some price recovery on small volume…

Neuralstem (AMEX: CUR) receives Patent Allowance: Patent Allowance for Compounds That Effect Neuronal Growth. Amex: CUR has received patent allowance for US Patent# 8,030,492 entitled: “Compositions to Effect Neuronal Growth.” The claims covered by the patent include both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo.

House bill would increase NIH’s budget but tighten restrictions: A House bill would increase the NIH’s 2012 budget by 3.3% but cut training programs and require a 9-1 ratio of extramural to intramural research programs. The bill also makes no mention of the institute’s plan to create the National Center for Advancing Translational Sciences and eliminate the National Center for Research Resources and would not fund the Cures Acceleration Network. If passed, the proposed budget must be reconciled with a Senate bill that would fund the NCATS and CAN.

Philanthropist Andy Grove drives medical research: Faced with Parkinson’s disease, former Intel chief Andy Grove has invested $30 million since 2005 to speed development of a cure. Grove has pushed drug companies to operate more like tech companies and build data-driven feedback loops. He has also proposed reforming clinical trial protocols to allow for smaller sample sizes and faster results, and he has designed a different measure for disease progression.